This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy | MicrobiomeTrials
← Back to trials NCT07023341
A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy Recruiting PHASE3 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2025-06-30Est. Completion: 2026-07-14
Enrollment target: 36 participantsLocations Kurume University Hospital, Kurume, Fukuoka, Japan Hyogo Prefectural HarimaHimeji General Medical Center, Himeji, Hyōgo, Japan Kobe City Medical Center General Hospital, Kobe, Hyōgo, Japan University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan Iwate Prefectural Central Hospital, Morioka, Iwate, Japan Kitasato University Hospital, Sagamihara, Kanagawa, Japan SHOWA Medical University Fujigaoka Hospital, Yokohama, Kanagawa, Japan Kochi Medical School Hospital, Nankoku, Kochi, Japan Mie University Hospital, Tsu, Mie-ken, Japan Tohoku University Hospital, Sendai, Miyagi, Japan University of the Ryukyus Hospital, Ginowan, Okinawa, Japan Matsushita Memorial Hospital, Moriguchi, Osaka, Japan National Cerebral and Cardiovascular Center, Suita, Osaka, Japan The University of Osaka Hospital, Suita, Osaka, Japan Hamamatsu University Hospital, Hamamatsu, Shizuoka, Japan Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan The University of Tokyo Hospital, Bunkyo, Tokyo, Japan Sakakibara Heart Institute, Fuchū, Tokyo, Japan Showa Medical University Koto Toyosu Hospital, Koto-ku, Tokyo, Japan Saiseikai Fukuoka General Hospital, Fukuoka, Japan Kumamoto University Hospital, Kumamoto, Japan Saiseikai Kumamoto Hospital, Kumamoto, Japan University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan Other microbiome trials you might be interested in Non-obstructive Hypertrophic Cardiomyopathy
FORTITUDE-HCM is a global, multicenter, double-blind, parallel-group, placebo-controlled Phase 2b study that will assess…
La Jolla, United States Est. completion Dec 2026
Cardiovascular Diseases Multi-omics Living Environments Pulmonary-cardiovascular Imaging
The DAILY project is a large-scale, multicenter, prospective initiative designed to establish a comprehensive bio-imagin…
Nanjing, China Est. completion Mar 31, 2028